Context Therapeutics (NASDAQ:CNTX) Stock Dropped to “Strong Sell” by Zacks Research

Posted by Brenda Bartman on Oct 14th, 2026

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday, Zacks reports.

CNTX has been the topic of a number of other reports. Weiss Ratings lowered Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Lifesci Capital downgraded Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Maxim Group reduced their price objective on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a research note on Thursday, August 6th. Finally, Wall Street Zen cut Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Context Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $6.17.

View Our Latest Research Report on Context Therapeutics

Context Therapeutics Trading Down 9.8%

Shares of Context Therapeutics stock opened at $0.28 on Monday. The stock has a market capitalization of $25.27 million, a price-to-earnings ratio of -0.57 and a beta of 1.71. The firm’s 50-day moving average price is $0.40 and its two-hundred day moving average price is $1.22. Context Therapeutics has a 1-year low of $0.27 and a 1-year high of $3.62.

Context Therapeutics (NASDAQ:CNTX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). As a group, equities research analysts predict that Context Therapeutics will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Context Therapeutics during the second quarter valued at approximately $3,417,000. Octagon Capital Advisors LP bought a new position in Context Therapeutics in the 1st quarter worth approximately $13,755,000. Blue Owl Capital Holdings LP bought a new position in Context Therapeutics in the 2nd quarter worth approximately $1,625,000. ADAR1 Capital Management LLC bought a new position in Context Therapeutics in the 2nd quarter worth approximately $416,000. Finally, Timothy G. Youngquist 2020 Irrevocable Trust acquired a new position in Context Therapeutics during the 2nd quarter worth $110,000. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Company Profile

(Get Free Report)

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.